MCKESSON CORP
No SEC Form 4 filings for $MCK in the last 30 days.
McKesson (NYSE:MCK) shares were little changed after earnings, down about 1% from recent highs. The company reported Q1 revenue of about $105.4B and adjusted EPS up 20% to $9.93, and it raised full-year adjusted EPS guidance. Q1 net income fell about 22% and basic EPS declined about 18%.
McKesson raised its fiscal 2027 adjusted profit forecast to $44.20 to $45 per share from $43.80 to $44.60 after first-quarter results beat estimates. Reuters reports Q1 revenue of $105.4B vs $103.74B expected, with adjusted profit $9.93 per share. Growth was driven by oncology and specialty drugs, and U.S. pharma sales rose 5% to $86.8B.
McKesson Medical-Surgical, a unit of McKesson Corp., said it plans to spin off into an independent publicly traded company and rebrand as Wellverse. The company expects to keep its Richmond, Virginia headquarters and local office space. It reported FY2026 revenue of $11.5B and operating profit of $938M. IPO is estimated for 2H 2027.
Over the past 7 days, alphai's AI scored 13 news stories mentioning MCK (MCKESSON CORP). Coverage has skewed bullish: 8 bullish, 5 neutral, and 0 bearish.
Recent MCK coverage spans earnings and corporate actions.
Despite stronger adjusted EPS and higher full-year guidance, the article frames a muted market reaction, implying traders are weighing regulatory and profit-mix risks.
Guidance raise tied to specialty and oncology demand suggests improved earnings visibility and supports near-term multiple expansion versus peers.
Spin-off execution details can affect parent capital structure, investor expectations, and near-term trading around separation mechanics.
Earnings beat-style profitability growth plus continued buybacks are likely supportive, but balance-sheet equity deterioration and rising redeemable noncontrolling interests add risk.
Guidance raise plus Q1 beat supports near-term earnings estimate revisions and sentiment for MCK.
alphai scores every news story that mentions MCK with an AI model for sentiment and relevance, and aggregates insider trades from MCKESSON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
McKesson (NYSE:MCK) shares were little changed after earnings, down about 1% from recent highs. The company reported Q1 revenue of about $105.4B and adjusted EPS up 20% to $9.93, and it raised full-year adjusted EPS guidance. Q1 net income fell about 22% and basic EPS declined about 18%.
6 min readMcKesson raised its fiscal 2027 adjusted profit forecast to $44.20 to $45 per share from $43.80 to $44.60 after first-quarter results beat estimates. Reuters reports Q1 revenue of $105.4B vs $103.74B expected, with adjusted profit $9.93 per share. Growth was driven by oncology and specialty drugs, and U.S. pharma sales rose 5% to $86.8B.
4 min readMcKesson Medical-Surgical, a unit of McKesson Corp., said it plans to spin off into an independent publicly traded company and rebrand as Wellverse. The company expects to keep its Richmond, Virginia headquarters and local office space. It reported FY2026 revenue of $11.5B and operating profit of $938M. IPO is estimated for 2H 2027.
3 min readMcKesson (NYSE: MCK) reported Q1 FY2027 results for the quarter ended June 30, 2026. Net income rose to $1,032 million from $831 million, diluted EPS to $8.15 from $6.25, and operating income to $1,036 million from $864 million. The company increased treasury stock via share repurchases and reported total assets of $88.33 billion.
4 min readMcKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.
2 min readMcKesson (MCK) reported fiscal Q1 2027 adjusted EPS of $9.93, above the $9.64 estimate, and revenue of $105.38B versus $103.82B. It raised full-year adjusted EPS guidance to $44.20-$45.00 and increased its quarterly dividend by 15%. Shares rose to $877.23 and $898.87 after hours.
6 min readMcKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.
4 min readMcKesson (NYSE:MCK) reported Q2 CY2026 sales of $105.4B, up 7.7% year on year, exceeding Wall Street revenue estimates by 1.2%. Non-GAAP adjusted EPS was $9.93, up from $8.26, beating consensus by 4.1%. Analysts expect revenue growth of 7.3% and full-year EPS to rise from $40.82 to $45.87.
6 min readMCKESSON CORP (MCK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 6 mck_exhibit991x6302026.htm EX-99.1 Document Exhibit 99.1 McKESSON REPORTS FISCAL 2027 FIRST QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, August 5, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the first quarter ended Jun
6 min readRx Savings Solutions, an Overland Park, Kansas prescription price transparency firm, confirmed layoffs as McKesson said it is streamlining operations. McKesson acquired Rx Savings Solutions in 2022. The statement said some roles will change, move, or be eliminated, without disclosing the number affected. McKesson previously laid off 78 employees in Buffalo in May.
2 min read
